The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Two of the vaccines we have for COVID-19 have the distinction of being the first mRNA vaccines to see widespread use in ...

With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger ...

Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger ...

Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management , as it targets up to 10% revenue ...

Researchers advance mRNA cancer therapies as France tests new methods, while the FDA approves Bayer’s Hyrnuo for HER2-mutated ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Because the flu shot is locked in six months early, it missed the strain now circulating through Canada – more ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 ...